Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

Orchestra BioMed 8/12/2024 Earnings Report

Orchestra BioMed logo
$4.72 -0.48 (-9.23%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Orchestra BioMed EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.78 million
Expected Revenue
$1.04 million
Beat/Miss
Missed by -$260.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Date
8/12/2024
Time
After Market Closes

Conference Call Resources

Orchestra BioMed Earnings Headlines

Orchestra BioMed to Present at Upcoming Investor Conferences
February 20 at 8:00 AM | globenewswire.com
Orchestra names Vivek Reddy as chairman of BACKBEAT study steering committee
February 19 at 12:59 AM | markets.businessinsider.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
February 18, 2025 | globenewswire.com
Barclays Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
February 15, 2025 | markets.businessinsider.com
Orchestra BioMed announces data on atrioventricular interval modulation therapy
February 12, 2025 | markets.businessinsider.com
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles